Systems and methods for detecting infectious diseases

Patent metadata

Field	Value
Publication number	US-9529976-B2
Application number	US-201414479241-A
Country	US
Kind code	B2
Filing date	Sep 5, 2014
Priority date	Sep 6, 2013
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.

First claim

What is claimed is:

1. A method of detecting a disease marker, comprising:
a) introducing a cartridge comprising a fluid sample and a swab sample into an automatic sample processing device having a housing, said cartridge carrying a vessel for holding a fluid sample, a vessel for holding swab, and a vessel containing a reagent, wherein said automatic sample processing device comprises:
1) a fluid handling system contained within said housing and comprising a movable pipette; and
2) an optical detector;
b) contacting a sample selected from said fluid sample and said swab sample, or a portion thereof, with a movable assay unit and with a reagent for the performance of an assay for the detection of a disease marker, said contacting comprising transporting said movable assay unit and said reagent by said fluid handling system within the housing, wherein said assay comprises isothermal non-cycling amplification of a double-stranded target nucleic acid molecule contacted with pairs of nucleic acid primers, said pairs comprising a first primer and a second primer, wherein said first primer comprises i) a template region complementary to at least a first portion of said double-stranded target nucleic acid molecule, and ii) a tail region, and said second primer comprises I) a template region complementary to at least a second portion of said double-stranded target nucleic acid molecule and II) a tail region containing a portion that is complementary to at least a portion of said tail region of said first primer;
c) contacting said sample, or portion thereof, with a DNA polymerase having strand displacement activity at a temperature of about 56° C. without thermal cycling, effective to initiate non-cycling nucleic acid amplification;
d) catalyzing the formation of an extension product of the first copy of the first primer, wherein the template-binding region, but not the tail region, of said first copy of the first primer anneals to the first strand of the double-stranded target nucleic acid molecule;
e) annealing the second primer to said extension product of the first copy of the first primer;
f) catalyzing the formation of an extension product of the second primer, wherein said extension product of the second primer is complementary to the extension product of the first copy of the first primer, and wherein the template-binding region, but not the tail region, of the second primer anneals to the extension product of the first copy of the first primer;
g) positioning said sample, or portion thereof, with said fluid handling system, at a location suitable for detection of an optical signal from the sample or portion thereof by said optical detector; and
h) detecting an optical signal indicative of the presence of a disease marker.

2. The method of claim 1 , comprising performing two or more assays for the detection of disease markers, and detecting two or more disease markers in one or more samples, or in one or more portions thereof.

3. The method of claim 1 , wherein said fluid sample comprises a blood sample.

4. The method of claim 1 , wherein said fluid sample comprises a urine sample.

5. The method of claim 1 , wherein said swab sample was obtained by swabbing a mouth, a throat, a nasal passage, a vaginal area, or other body cavity of a subject.

6. The method of claim 1 , wherein said swab sample comprises a throat sample obtained using said swab, and said fluid sample comprises a blood sample.

7. The method of claim 1 , comprising detecting the presence of a nucleic acid disease marker and a protein disease marker.

8. The method of claim 1 , wherein said sample has a volume of less than about 500 microliters.

9. The method of claim 1 , comprising performing two or more assays for the detection of disease markers, and detecting two or more disease markers in said samples, or in one or more portions thereof.

10. The method of claim 9 , comprising detecting the presence of a nucleic acid disease marker and a protein disease marker.

11. The method of claim 1 , wherein said disease marker is selected from a nucleic acid disease marker, a protein disease marker, a saccharide, a prostaglandin, a cytokine, histamine, a steroid, and a marker for inflammation.

12. The method of claim 9 , wherein said two or more disease markers are selected from a nucleic acid disease marker, a protein disease marker, a saccharide, a prostaglandin, a cytokine, histamine, a steroid, and a marker for inflammation.

13. The method of claim 1 , wherein said disease marker is a marker for inflammation selected from prostaglandins, tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-12 (IL-12), interferon gamma (IF-γ), bradykinin, complement system molecules, blood-clotting factors, C-reactive protein, erythrocyte sedimentation rate (ESR), white blood cell count, and morphological changes in blood and other cells.

14. The method of claim 1 , wherein said disease marker is a marker for a disease-causing agent, wherein said disease-causing agent is selected from the group of disease-causing organisms consisting of a virus, a bacterium, a mycoplasm, a fungus, a yeast, and other micro-organisms.

15. The method of claim 1 , wherein the disease marker is a marker for a disease-causing agent selected from the group consisting of Influenza A Matrix protein, Influenza H3N2, Influenza H1N1 (seasonal), Influenza H1N1 (novel), Influenza B, Streptococcus pyogenes (A), Mycobacterium Tuberculosis, Staphylococcus aureus (MR), Staphylococcus aureus (RS), Bordetella pertussis (whooping cough), Streptococcus agalactiae (B), Influenza H5N1, Influenza H7N9, Adenovirus B, Adenovirus C, Adenovirus E, Hepatitis b, Hepatitis c, Hepatitis delta, Treponema pallidum , HSV-1, HSV-2, HIV-1, HIV-2, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Malaria, West Nile Virus, Ebola virus, Marburg virus, Cueva virus, Trypanosoma cruzi (Chagas), Klebsiella pneumoniae (Enterobacteriaceae spp), Klebsiella pneumoniae carbapenemase (KPC), Epstein Barr Virus (mono), Rhinovirus, Parainfluenza virus (1), Parainfluenza virus (2), Parainfluenza virus (3), Parainfluenza virus (4a), Parainfluenza virus (4b), Respiratory syncytial virus (RSV) A, Respiratory syncytial virus (RSV) B, Coronavirus 229E, Coronavirus HKU1, Coronavirus OC43, Coronavirus NL63, Novel Coronavirus, Bocavirus, human metapneumovirus (HMPV), Streptococcus pneumoniae (penic R), Streptococcus pneumoniae (S), Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella parpertussis, Haemophilus influenzae (ampic R), Haemophilus influenzae (ampic S), Moraxella catarrhalis, Pseudomonas spp ( aeruginosa ), Haemophilus parainfluenzae, Enterobacter cloacae (Enterobacteriaceae spp), Enterobacter aerogenes (Enterobacteriaceae spp), Serratia marcescens (Enterobacteriaceae spp), Acinetobacter baumanii, Legionella spp, Escherichia coli, Candida, Chlamydia trachomatis , Human Papilloma Virus, Neisseria gonorrhoeae, plasmodium , and Trichomonas (vagin).

16. The method of claim 9 , comprising detecting a disease marker in a blood sample and detecting a disease marker in a sample obtained from a swab, wherein one of said disease markers is a marker for inflammation, and one of said disease markers a marker for a disease-causing agent.

17. The method of claim 16 , wherein said disease marker for inflammation is selected from prostaglandins, tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-12 (IL-12), interferon gamma (IF-γ), bradykinin, complement system molecules, blood-clotting factors, C-reactive protein

Assignees

• Theranos Inc

Inventors

• Lui Clarissa
• Holmes Elizabeth A

Classifications

• G16H50/20

  for computer-aided diagnosis, e.g. based on medical expert systems · CPC title

• G16H20/10

  relating to drugs or medications, e.g. for ensuring correct administration to patients · CPC title

• G01N2469/20

  Detection of antibodies in sample from host which are directed against antigens from microorganisms · CPC title

• Y10T436/11

  Automated chemical analysis · CPC title

• C12Q2600/158

  Expression markers · CPC title